Urology

The FDA’s approval of the first gene therapy to treat high-risk non-muscle-invasive bladder cancer follow a multicenter clinical trial.

The new antibacterial drug was approved after it was proven safe and effective in a study of 448 patients with complicated UTIs.

The FDA has approved a new option for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

The FDA has approved a drug for the treatment of patients with with locally advanced or metastatic urothelial carcinoma.

The FDA granted accelerated approval for a new treatment for patients with locally advanced or metastatic urothelial carcinoma.

The FDA has expanded the use of Opdivo (nivolumab) for the treatment of patients with urothelial carcinoma, the most common form of bladder cancer.